Chinese Academy of Medical Sciences COVID-19 vaccine

­­­Review in Chinese Medical Journal Explores Effect of Gut Microbiota on Inflammatory Bowel Disease

Retrieved on: 
Tuesday, January 18, 2022 - 1:42pm

"Dysbiosis" or an imbalance in their populations can, however, contribute to the pathology of gastrointestinal diseases such as inflammatory bowel disease (IBD).

Key Points: 
  • "Dysbiosis" or an imbalance in their populations can, however, contribute to the pathology of gastrointestinal diseases such as inflammatory bowel disease (IBD).
  • Researchers from the Peking Union Medical College, China and the Chinese Academy of Medical Sciences have delved deeper into understanding multi-dimensional dysbiosis and technologies that can aid the diagnosis and treatment of IBD.
  • Next, they describe the "mycobiome" or fungal microbiota, that has been relatively less explored, and their interplay with bacterial populations.
  • Finally, the review highlights therapeutic strategies such as "fetal microbiota transplantation" and "supplementary probiotics" that can help replenish gut microbiota and restore balance.

Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance

Retrieved on: 
Wednesday, January 12, 2022 - 1:26am

Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.

Key Points: 
  • Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.
  • Compared to the phase I clinical trial results of similar products, it demonstrated excellent safety and immunogenicity.
  • At present, the phase I clinical trials of all 3 China's mRNA vaccines are carried out at the Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, among which the first mRNA vaccine is already under phase III clinical trial overseas.
  • At the meeting, top-notch experts acclaimed the phase I results of the mRNA COVID-19 vaccine (LVRNA009) of AIM Vaccine.

IMPULSE DYNAMICS ANNOUNCES FIRST OPTIMIZER IMPLANT IN CHINA

Retrieved on: 
Monday, November 1, 2021 - 12:23pm

MARLTON, N.J., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure, today announced the first implantation of a patient in China with its innovative Optimizer system delivering CCM therapy.

Key Points: 
  • MARLTON, N.J., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure, today announced the first implantation of a patient in China with its innovative Optimizer system delivering CCM therapy.
  • Cardiologist Dr. Hua Wei from the renowned Fuwai Hospital of the Chinese Academy of Medical Sciences performed the successful implant procedure.
  • For the vast majority of patients with heart failure, I think the implant performed today has a significant meaning for the future.
  • Impulse Dynamics, based in Marlton, N.J., is dedicated to helping healthcare providers enhance the lives of people with heart failure by transforming how the condition is treated.